Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Swerdlow, 2008
Cherian, 2012
Wood, 2004, Multicolor immunophenotyping: human immune system hematopoiesis, Methods Cell Biol, 75, 559, 10.1016/S0091-679X(04)75023-2
Wood, 2007, Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia, Clin Lab Med, 27, 551, 10.1016/j.cll.2007.05.006
Kussick, 2003, Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders, Am J Clin Pathol, 120, 854, 10.1309/CAUT52HJ535P9UG2
Borowitz, 1993, Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis, Am J Clin Pathol, 100, 534, 10.1093/ajcp/100.5.534
Stelzer, 1993, CD45 gating for routine flow cytometric analysis of human bone marrow specimens, Ann N Y Acad Sci, 677, 265, 10.1111/j.1749-6632.1993.tb38783.x
Wood, 2007, 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia, Cytometry B Clin Cytom, 72, S14, 10.1002/cyto.b.20363
Yang, 2005, Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations, Am J Clin Pathol, 124, 930, 10.1309/T903Y1FY5WKK9EEY
Kaleem, 2003, Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data, Arch Pathol Lab Med, 127, 42, 10.5858/2003-127-42-FCAOA
Khalidi, 1998, The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities, Am J Clin Pathol, 109, 211, 10.1093/ajcp/109.2.211
Zheng, 2008, A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China, Cytometry B Clin Cytom, 74, 25, 10.1002/cyto.b.20368
Loken, 1987, Flow cytometric analysis of human bone marrow: I. Normal erythroid development, Blood, 69, 255, 10.1182/blood.V69.1.255.255
Koike, 1987, Cell surface phenotyping of megakaryoblasts, Blood, 69, 957, 10.1182/blood.V69.3.957.957
San Miguel, 1988, Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics, Blood, 72, 402, 10.1182/blood.V72.2.402.402
Kafer, 1999, Intracellular expression of CD61 precedes surface expression, Ann Hematol, 78, 472, 10.1007/s002770050601
Betz, 1992, False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts, Blood, 79, 2399, 10.1182/blood.V79.9.2399.2399
Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544
Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569
De, 2007, Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia, Am J Clin Pathol, 128, 550, 10.1309/JVALJNL4ELQMD536
Khoury, 2004, Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21), Mod Pathol, 17, 1211, 10.1038/modpathol.3800168
Khoury, 2003, Acute myelogenous leukemia with t(8;21)–identification of a specific immunophenotype, Leuk Lymphoma, 44, 1713, 10.1080/1042819031000116698
Porwit-MacDonald, 1996, Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21), Blood, 87, 1162, 10.1182/blood.V87.3.1162.bloodjournal8731162
Kita, 1992, Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34, Blood, 80, 470, 10.1182/blood.V80.2.470.470
Chen, 2008, Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan, Int J Lab Hematol, 30, 133, 10.1111/j.1751-553X.2007.00913.x
Yang, 2007, Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation, Am J Hematol, 82, 1, 10.1002/ajh.20739
Baer, 1997, Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22), Blood, 90, 1643, 10.1182/blood.V90.4.1643
Paschka, 2006, Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study, J Clin Oncol, 24, 3904, 10.1200/JCO.2006.06.9500
Shimada, 2006, KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group, Blood, 107, 1806, 10.1182/blood-2005-08-3408
Di Noto, 2007, Flow cytometry analysis of acute promyelocytic leukemia: the power of 'surface hematology', Leukemia, 21, 4, 10.1038/sj.leu.2404412
Orfao, 1999, The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements, Haematologica, 84, 405
Albano, 2006, The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes, Haematologica, 91, 311
Biondi, 1995, CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint, Leukemia, 9, 1461
Ferrara, 2000, CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy, J Clin Oncol, 18, 1295, 10.1200/JCO.2000.18.6.1295
Ito, 2004, Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia, Leuk Lymphoma, 45, 1783, 10.1080/10428190410001683624
Murray, 1999, CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?, J Clin Oncol, 17, 293, 10.1200/JCO.1999.17.1.293
Masamoto, 2009, Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy, Br J Haematol, 144, 798, 10.1111/j.1365-2141.2008.07507.x
Oelschlaegel, 2009, HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia, Cytometry B Clin Cytom, 76, 321, 10.1002/cyto.b.20475
Wetzler, 2003, HLA-DR antigen-negative acute myeloid leukemia, Leukemia, 17, 707, 10.1038/sj.leu.2402865
Fenaux, 1993, Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group, Blood, 82, 3241, 10.1182/blood.V82.11.3241.3241
Kanamaru, 1995, All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group, Blood, 85, 1202, 10.1182/blood.V85.5.1202.bloodjournal8551202
Tallman, 2002, All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol, Blood, 100, 4298, 10.1182/blood-2002-02-0632
Ferrari, 2012, Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations, Hematol Oncol, 30, 109, 10.1002/hon.1011
Baer, 1998, Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry, Leukemia, 12, 317, 10.1038/sj.leu.2400933
Munoz, 2003, Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells, Leukemia, 17, 76, 10.1038/sj.leu.2402708
Creutzig, 1995, Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87, Blood, 86, 3097, 10.1182/blood.V86.8.3097.3097
Chang, 2004, Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome, Leuk Res, 28, 1007, 10.1016/j.leukres.2004.01.006
Mrozek, 2007, Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?, Blood, 109, 431, 10.1182/blood-2006-06-001149
Falini, 2005, Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype, N Engl J Med, 352, 254, 10.1056/NEJMoa041974
Falini, 2007, Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features, Blood, 109, 874, 10.1182/blood-2006-07-012252
Haferlach, 2009, AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features, Blood, 114, 3024, 10.1182/blood-2009-01-197871
Kussick, 2004, A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication, Leukemia, 18, 1591, 10.1038/sj.leu.2403458
Thalhammer-Scherrer, 2002, The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination, Am J Clin Pathol, 117, 380, 10.1309/C38D-D8J3-JU3E-V6EE
Bene, 2009, Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!, Haematologica, 94, 891, 10.3324/haematol.2009.007799
Owaidah, 2006, Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system, Leukemia, 20, 620, 10.1038/sj.leu.2404128
Weinberg, 2010, Mixed-phenotype acute leukemia: historical overview and a new definition, Leukemia, 24, 1844, 10.1038/leu.2010.202
Xu, 2009, Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population, Haematologica, 94, 919, 10.3324/haematol.2008.003202
Garnache-Ottou, 2009, Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia, Br J Haematol, 145, 624, 10.1111/j.1365-2141.2009.07679.x
Garnache-Ottou, 2007, Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?, Br J Haematol, 136, 539, 10.1111/j.1365-2141.2006.06458.x
Herling, 2007, CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells, Am J Clin Pathol, 127, 687, 10.1309/FY6PK436NBK0RYD4
Buccisano, 2006, The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia, Leukemia, 20, 1783, 10.1038/sj.leu.2404313
Freeman, 2013, Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia, J Clin Oncol, 31, 4123, 10.1200/JCO.2013.49.1753
Jourdan, 2013, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, 121, 2213, 10.1182/blood-2012-10-462879
Kern, 2004, Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia, Blood, 104, 3078, 10.1182/blood-2004-03-1036
Kronke, 2011, Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group, J Clin Oncol, 29, 2709, 10.1200/JCO.2011.35.0371
San Miguel, 2001, Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification, Blood, 98, 1746, 10.1182/blood.V98.6.1746
Terwijn, 2013, High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study, J Clin Oncol, 31, 3889, 10.1200/JCO.2012.45.9628
Venditti, 2000, Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia, Blood, 96, 3948, 10.1182/blood.V96.12.3948
Yin, 2012, Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, 120, 2826, 10.1182/blood-2012-06-435669
Al-Mawali, 2009, The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia, Am J Clin Pathol, 131, 16, 10.1309/AJCP5TSD3DZXFLCX
Wood, 2016, Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry, Cytometry B Clin Cytom, 90, 47, 10.1002/cyto.b.21239
Feller, 2013, Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting, Blood Cancer J, 3, e129, 10.1038/bcj.2013.27
Macedo, 1995, Characterization of aberrant phenotypes in acute myeloblastic leukemia, Ann Hematol, 70, 189, 10.1007/BF01700374
Reading, 1993, Expression of unusual immunophenotype combinations in acute myelogenous leukemia, Blood, 81, 3083, 10.1182/blood.V81.11.3083.3083
Al-Mawali, 2008, Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry, Am J Clin Pathol, 129, 934, 10.1309/FY0UMAMM91VPMR2W
Borowitz, 2005, Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group, Cytometry B Clin Cytom, 68, 18, 10.1002/cyto.b.20071
Zeijlemaker, 2014, Tumor heterogeneity makes AML a “moving target” for detection of residual disease, Cytometry B Clin Cytom, 86, 3, 10.1002/cytob.21134
Baer, 2001, High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361), Blood, 97, 3574, 10.1182/blood.V97.11.3574
Langebrake, 2005, Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring, Cytometry B Clin Cytom, 63, 1, 10.1002/cyto.b.20037